Tetracyclines in malaria

Gaillard, Tiphaine; Madamet, Marylin; Pradines, Bruno

doi:10.1186/s12936-015-0980-0

Cited by 93 publications

(75 citation statements)

References 108 publications

(108 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To test the specificity of doxycycline-induced disease tolerance across infection models, we used a model of systemic fungal infection induced by intravenous injection of Candida albicans and found no differences in survival rates of treated mice ( Figure S1E). Similarly, in a model of cerebral malaria induced by Plamodium berghei Anka no differences were found in survival rates ( Figure S1F) despite reduced percentage of infected red blood cells upon doxycycline treatment ( Figure S1G), in line with the well-established anti-malarial effects of the drug (Gaillard et al, 2015). These results suggest that doxycycline-induced mechanisms of disease tolerance are specific for bacterial infections.…”

Section: Doxycycline Confers Protection In a Mouse Model Of Bacterialsupporting

confidence: 57%

Host-dependent induction of disease tolerance to infection by tetracycline antibiotics

Colaço

Barros

Neves‐Costa

et al. 2019

Preprint

View full text Add to dashboard Cite

Synergy of resistance and disease tolerance mechanisms is necessary for an effectiveimmune response leading to survival and return to homeostasis when an organism is challenged by infection. Antibiotics are used for their resistance enhancement capabilities by decreasing pathogen load, but several classes have long been known to have beneficial effects that cannot be explained strictly on the basis of their capacity to control the infectious agent. Here we report that tetracycline antibiotics, a class of ribosome-targeting drugs, robustly protects against sepsis by inducing disease tolerance, independently from their direct antibiotic properties. Mechanistically, we find that mitochondrial inhibition of protein synthesis perturbs the electron transfer chain and leads to improved damage repair in the lung and fatty acid oxidation and glucocorticoid sensitivity in the liver. Using a partial and acute deletion of CRIF1 in the liver, a critical mitoribosomal component for protein synthesis, we find that mice are protected against bacterial sepsis, an observation which is phenocopied by the transient inhibition of complex I of ETC by phenformin. Together, we demonstrate that ribosome-targeting antibiotics are beneficial beyond their antibacterial activity and that mitochondrial protein synthesis inhibition leading to ETC perturbation is a novel mechanism for the induction of disease tolerance.

show abstract

Section: Doxycycline Confers Protection In a Mouse Model Of Bacterialsupporting

confidence: 57%

Host-dependent induction of disease tolerance to infection by tetracycline antibiotics

Colaço

Barros

Neves‐Costa

et al. 2019

Preprint

View full text Add to dashboard Cite

show abstract

“…Because Malarone and doxycycline require daily administration for malaria prevention, compliance is a problem (9). In addition, doxycycline is contraindicated in pregnant women and younger children, and it is also associated with phototoxicity (10,11). Mefloquine is not recommended in some Southeast Asian countries where mefloquine resistance has emerged, and it is not recommended for pregnant women, infants, and persons with neuropsychiatric disorders (12).…”

mentioning

confidence: 99%

Randomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast Asia

Yang

Wang

Liu

et al. 2018

Antimicrob Agents Chemother

View full text Add to dashboard Cite

New prophylactic drugs against malaria infections are urgently needed. We conducted randomized, double-blind, placebo-controlled, phase 2 trials of a new antimalarial drug combination, naphthoquine-azithromycin (NQAZ), to determine its safety and protective efficacy in a low-endemicity area of Southeast Asia. In the first trial, 127 healthy volunteers were randomized to receive two single doses of either 400 mg of NQAZ (200 mg of each drug), 800 mg of NQAZ (400 mg of each drug), or placebo on day 0 and day 30. Weekly follow-ups were performed for 2 months, and physical and clinical laboratory exams were done during the second and eighth week. Both drug regimens were well tolerated, without any serious adverse events. Four adverse events (transient and slight elevations of serum transaminase concentrations) were found only in the two drug-treated groups and thus might be drug-related. In the second trial, 353 volunteer villagers were randomized into the same three groups as in the first trial, and malaria infections were followed for a month. For the intention-to-treat analysis, both regimens offered greater than 90% prophylactic efficacies against all malaria infections. When the analysis was done according to parasite species, 400 mg and 800 mg NQAZ provided 81.63 and 90.59% prophylactic efficacies, respectively, against infections, whereas both offered 100% prophylactic efficacy against and These trials showed that NQAZ had a good safety profile, and monthly single doses of 400 mg or 800 mg for adults offered excellent prophylaxis against malaria infections, especially the two relapsing species.

show abstract

“…To overcome this problem new therapeutic strategies are been developed. Many other drugs formulations have recently been developed such as combination of molecules (artemisinin-based combination therapy) [4] and use of antibiotics that have been shown to be effective against malaria parasites [5, 6]. …”

Section: Introductionmentioning

confidence: 99%

“…The term of antibiotic in this review defined any compound that has been used to treat bacterial infections and their analogues developed if there were active against Plasmodium falciparum . Two families, tetracyclines and macrolides and their derivatives, have been the focus of many studies in the past 30 years and were previously described in two reviews [5, 6]. However, other antibiotics against malaria parasites could be developed in the future.…”

Section: Introductionmentioning

confidence: 99%

Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria?

Gaillard

Madamet

Tsombeng

et al. 2016

Malar J

Self Cite

View full text Add to dashboard Cite

Malaria, a parasite vector-borne disease, is one of the most significant health threats in tropical regions, despite the availability of individual chemoprophylaxis. Malaria chemoprophylaxis and chemotherapy remain a major area of research, and new drug molecules are constantly being developed before drug-resistant parasites strains emerge. The use of anti-malarial drugs is challenged by contra-indications, the level of resistance of Plasmodium falciparum in endemic areas, clinical tolerance and financial cost. New therapeutic approaches are currently needed to fight against this disease. Some antibiotics that have shown potential effects on malaria parasite have been recently studied in vitro or in vivo intensively. Two families, tetracyclines and macrolides and their derivatives have been particularly studied in recent years. However, other less well-known have been tested or are being used for malaria treatment. Some of these belong to older families, such as quinolones, co-trimoxazole or fusidic acid, while others are new drug molecules such as tigecycline. These emerging antibiotics could be used to prevent malaria in the future. In this review, the authors overview the use of antibiotics for malaria treatment.

show abstract

Tetracyclines in malaria

Cited by 93 publications

References 108 publications

Host-dependent induction of disease tolerance to infection by tetracycline antibiotics

Host-dependent induction of disease tolerance to infection by tetracycline antibiotics

Randomized, Double-Blind, Placebo-Controlled Studies to Assess Safety and Prophylactic Efficacy of Naphthoquine-Azithromycin Combination for Malaria Prophylaxis in Southeast Asia

Antibiotics in malaria therapy: which antibiotics except tetracyclines and macrolides may be used against malaria?

Contact Info

Product

Resources

About